Appendiceal low-grade pseudomyxoma peritonei recurrence with splenic invasion and parastomal hernia

Recurrence of low-grade appendiceal pseudomyxoma peritonei (PMP) with splenic invasion and parastomal hernia is exceptionally rare. We present a 47-year-old female with recurrent PMP, four years post-cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). She presented with abdominal distension, splenic invasion, and parastomal hernia. Imaging revealed extensive peritoneal and pelvic metastases, splenic lesions, and parastomal hernia. Intraoperative findings confirmed widespread pseudomyxoma, involving the spleen and diaphragm. She underwent CRS, splenectomy, tumor resection, adhesiolysis, partial colectomy, hernia repair, and diaphragmatic reconstruction, followed by intraoperative HIPEC. Despite postoperative complications, the patient recovered well with no recurrence over 20 months. This case underscores the challenges of managing recurrent PMP with splenic metastases and parastomal hernias, highlighting the importance of multidisciplinary collaboration and personalized therapeutic strategies.

1 Introduction

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by the accumulation of abundant mucin within the abdominal cavity, involving the peritoneum, omentum, and pelvic organs (1). It typically originates from the rupture of mucinous tumors of the appendix. Due to its unique biological behavior, PMP primarily spreads intraperitoneally, with lymphatic and hematogenous metastases being relatively rare (2). Consequently, reports of PMP metastasizing to solid organs like the spleen are scarce, and the literature documenting such cases is very limited.

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard treatment for PMP. The aim is to surgically remove the tumors deposits and administer intraperitoneal chemotherapy to minimize the number of residual tumor cells (3). Although CRS combined with HIPEC can effectively control the progression of PMP, its recurrence rate remains high. Recurrent PMP often manifests as the re-emergence of localized or systemic disease, potentially accompanied by symptoms such as abdominal pain, ascites, small bowel obstruction, malnutrition, intra-abdominal adhesions, and gastrointestinal bleeding (4, 5).

 Parastomal hernia is an uncommon complication of recurrent PMP, primarily driven by increased intra-abdominal pressure from high-volume mucinous tumor recurrence. This pressure exacerbates weakness at the stoma site, predisposing to herniation. Following CRS and HIPEC, the risk of abdominal wall hernias increases due to tissue trauma and compromised abdominal wall integrity.

Here, we report a case of recurrent PMP four years after undergoing CRS combined with HIPEC treatment. The patient developed rare splenic invasion and concurrent parastomal hernia formation, adding complexity to the subsequent surgical intervention. Through this case presentation, we aim to explore the biological characteristics, recurrence patterns, and implications for treatment strategies of PMP, providing valuable insights for clinical practice.

2 Case report

In July 2022, a 47-year-old female presented with a six-month history of abdominal distension. Four years prior, she had undergone CRS combined with open HIPEC for appendiceal PMP, which included total hysterectomy, bilateral salpingo-oophorectomy, and right hemicolectomy. Her preoperative PCI score was 30, and postoperative PCI was reduced to 6. Thermal ablation was applied to peritoneal tumors, with residual tumors located in the pelvic cavity and the diaphragm. Cytoreduction was incomplete, classified as CC2. Postoperatively, the patient developed an intraperitoneal infection leading to an anastomotic dehiscence of the ileocolic anastomosis, necessitating a double-barrel ileostomy and colostomy. Three months later, the colostomy was reversed, leaving the ileostomy in place. Systemic chemotherapy was not administered, as it was not indicated for her low-grade PMP.

Physical examination revealed a stoma in the right lower abdomen, significant bulging on the right side of the abdomen (Figure 1), palpable hard masses, and shifting dullness. Serum carcinoembryonic antigen (CEA) levels elevated to 45.02 ng/ml, and CA19-9 levels markedly increased to 68.08 U/ml, Enhanced CT imaging revealed widespread low-density lesions in the bilateral subdiaphragmatic, hepatic, and pelvic regions, heterogeneous density lesions in the spleen, and diffuse thickening of the peritoneum in some areas. A mass was observed beside the original right upper abdominal colostomy, with protrusion of the small intestine into the subcutaneous layer of the abdominal wall. (Figure 2) Subsequent gastrointestinal contrast imaging confirmed these findings (Figure 3), consistent with the clinical features of progressive pseudomyxoma peritonei with extensive pelvic metastases, splenic invasion, and parastomal hernia.

Figure 1

Figure 1. The right abdomen demonstrates a prominent protrusion (highlighted in red).

Figure 2

Figure 2. (a,b) The abdominal CT axial and sagittal sections demonstrate a low-density occupying lesion in the spleen (red arrow). (c,d): Adjacent to the original colostomy site, there is a herniation of the small intestine and surrounding tissues (highlighted in red).

Figure 3

Figure 3. The gastrointestinal contrast study suggests hernia contents containing intestinal loops.

During the surgery, extensive upper abdominal adhesions were identified, and an 8 cm hernia sac was observed adjacent to the original right ascending colon stoma (Figure 4a). Approximately 2,000 ml of mucinous, blood-tinged ascites was present. There was widespread deposition of mucinous tumor between the peritoneum, liver, and diaphragm, as well as within the hepatic round ligament. Portions of the peritoneum displayed thickened, “pancake-like” deposits, measuring up to 10 cm in diameter. Small, gravel-like mucinous deposits were also found on the greater omentum. Metastatic nodules were noted between the spleen and left upper abdominal wall, with significant infiltration into the diaphragmatic peritoneum. The PCI at laparotomy was calculated to be 24.

Figure 4

Figure 4. (a) the contents of the hernia are the small intestine and tumors. (b) Surgical resection specimen showing adhesion between the ileum and ascending colon (red arrow); large peritoneal tumor (yellow arrow); splenomegaly (black arrow).

Cytoreductive surgery was performed, including splenectomy, peritoneal tumor resection, adhesiolysis, and partial descending colon resection (Figure 4b), resulting in a postoperative peritoneal cancer index (PCI) score of 6 and a completeness of cytoreduction (CC) score of 1. Concurrently, parastomal hernia repair (using UPA31015 mesh, manufactured by Johnson & Johnson International c/o European Logistics Centre) composed of approximately equal amounts of absorbable monofilament polyglecaprone-25 fibers and non-absorbable polypropylene monofilament fibers. Left diaphragmatic repair were conducted, with closed thoracic drainage, followed by open HIPEC treatment. Pathological confirmation revealed a low-grade mucinous tumor of the appendix, with immunohistochemistry showing (spleen) CDX2+, Muc2+, Muc5+ (Figure 5).

Figure 5

Figure 5. Spleen and immunohistochemistry: under the light microscope, cattered cystic lesions are observed in the splenic tissue, filled with mucoid material, surrounded by chronic inflammatory reaction. Splenic white pulp (blue arrow), single-layered tumor cells (yellow arrow), mucin (red arrow). (a) HE 30x, (b) HE 100x, (c) HE 200x, (d) Positive expression of MUC2. (e) Mucinous tissue. HE 100x. (f) Positive expression of CDX2.

Unfortunately, the patient experienced hypovolemic shock postoperatively, requiring fluid resuscitation, blood transfusion, and vasopressor therapy (Figure 6). On the 7th day, wound infection occurred, and based on bacterial culture results (Enterococcus avium) and susceptibility testing, meropenem, vancomycin, and levofloxacin were administered sequentially. The patient showed improvement and was discharged on the 25th postoperative day. Radiological surveillance was initiated with a baseline contrast-enhanced CT three months postoperatively, followed by contrast-enhanced CT every six months for the first two years and annually thereafter for 5–10 years. A 20-month follow-up showed no evidence of recurrence.

Figure 6

Figure 6. (a) changes in blood pressure 2 days after surgery suggest hypovolemic shock. (b) Changes in fluid intake and output after surgery.

3 Discussion

PMP is a rare clinical syndrome, with over 95% of cases originating from the appendix and gastrointestinal tract. In the 1990s, Professor Sugarbaker (6) proposed the CRS combined with HIPEC combined modality for treating PMP, involving surgical resection of tumor tissue followed by intraperitoneal hyperthermic chemotherapy to eradicate residual microscopic foci and free tumor cells within the abdominal cavity, thus reducing tumor recurrence or prolonging the interval to recurrence. Results from multicenter retrospective studies have shown that patients undergoing CRS combined with HIPEC treatment may achieve a 10-year survival rate of over 60%, making this combined modality the preferred treatment approach for PMP (3, 4, 7).

However, nearly 30% of PMP patients experience recurrence following CRS combined with HIPEC (8), with studies indicating that a PCI > 20 is considered a risk factor for early recurrence, elevated preoperative CEA levels predict early recurrence and poorer survival rates in PMP, and higher CC scores correlate with a greater risk of recurrence (4, 9). Some scholars also suggest that regular postoperative systemic chemotherapy can reduce the risk of PMP recurrence (10). Current views suggest that systemic chemotherapy may be beneficial for patients with unresectable high-grade appendiceal adenocarcinoma, particularly in cases where tumor residue remains post-surgery. However, chemotherapy is generally not recommended for low-grade tumors, as they exhibit low cellular turnover and are typically resistant to such treatments (11). Recent advances in precision oncology and targeted therapies are being explored as we gain a better understanding of the genomic landscape of these tumors.

Although the spleen is a common metastatic site for malignant tumors, its metastasis typically occurs through hematogenous dissemination from primary or secondary tumors (12). However, both primary and recurrent metastasis of PMP to the spleen are rare, often presenting as diffuse intraperitoneal mucinous deposits, with lymphatic and hematogenous metastases being relatively infrequent (13). In our case, gelatinous material was observed upon splenic incision, and the exact metastatic route remains unknown, suggesting possible infiltration into the spleen or hematogenous dissemination.

In managing recurrent PMP with parastomal hernia, we propose several treatment strategies. Multidisciplinary team consultation is essential for thorough patient assessment, including cardiovascular and pulmonary evaluations to minimize perioperative risks. During abdominal wall repair, the choice of mesh is critical; we used Johnson & Johnson's UPA31015 (absorbable monofilament polyglecaprone-25 fibers and non-absorbable polypropylene monofilament fibers) mesh to reinforce the abdominal wall and prevent hernia recurrence. Postoperative care focused on reducing intraperitoneal fluid accumulation and managing intraoperative bleeding to avoid hypotension from decreased intra-abdominal pressure, necessitating abdominal binding and blood pressure monitoring. Tailored fluid and nutrition management was crucial for maintaining stable hemodynamics and promoting recovery. Effective pain management, including the use of rectus sheath block, was employed to enhance patient comfort. This case also illustrates the success of iterative CRS and HIPEC in treating recurrent PMP, even after initial suboptimal cytoreduction (CC2) and high-volume disease. Despite incomplete initial resection, the patient remained disease-free for four years, supporting the feasibility of repeat CRS and HIPEC in low-grade PMP with prolonged disease-free intervals. Residual disease, primarily in the upper abdomen and pelvis, was effectively managed during the second surgery, highlighting the potential for favorable outcomes with aggressive re-intervention, even following a CC2 resection.

4 Conclusion

This case presents a rare occurrence of recurrent low-grade appendiceal mucinous neoplasm with PMP, accompanied by parastomal hernia and splenic metastasis. When managing recurrent cases, preoperative assessment, intraoperative procedures, and postoperative monitoring are crucial. For patients with accompanying parastomal hernia, a multidisciplinary team approach and personalized treatment plans can enhance survival rates and improve prognosis. Prompt surgical removal of splenic metastasis is important to prevent further spread and is a key therapeutic approach. However, further research and practice are needed to optimize treatment strategies.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethical approval for this study was obtained from the Ethics Committee of Central Hospital Affiliated to Shandong First Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

QL: Writing – original draft. JJ: Resources, Writing – review & editing. GY: Writing – review & editing. PG: Conceptualization, Writing – review & editing. CL: Conceptualization, Funding acquisition, Project administration, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Science and Technology Development Program of Jinan Municipal Health Commission (Grant No. 2019-2-06, 2023-2-18;2023-2-17;2023-1-10).

Acknowledgments

We sincerely thank all the physicians involved in the treatment for providing invaluable expertise in developing the patient's treatment plan.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

PMP, pseudomyxoma peritonei; CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; CC, completeness of cytoreduction; PCI, peritoneal cancer index.

References

1. Liu S, Liu X, Ma R, Yu S, Lu L, Lin Y, et al. Global trends in research of pseudomyxoma peritonei: a bibliometric and visualization analysis. Front Oncol. (2024) 14:1323796. doi: 10.3389/fonc.2024.1323796

PubMed Abstract | Crossref Full Text | Google Scholar

2. Arshi J, Peter AD, Liang Y, Hao Y. Confined low grade appendiceal mucinous neoplasm with coexisting distant metastasis. In Vivo. (2024) 38(1):295–8. doi: 10.21873/invivo.13438

PubMed Abstract | Crossref Full Text | Google Scholar

3. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. (2012) 30(20):2449–56. doi: 10.1200/jco.2011.39.7166

PubMed Abstract | Crossref Full Text | Google Scholar

4. Baumgartner JM, Srivastava A, Melnitchouk N, Drage MG, Huber AR, Gonzalez RS, et al. A multi-institutional study of peritoneal recurrence following resection of low-grade appendiceal mucinous neoplasms. Ann Surg Oncol. (2021) 28(8):4685–94. doi: 10.1245/s10434-020-09499-y

PubMed Abstract | Crossref Full Text | Google Scholar

5. Soto Llanes JO, Dosal Limón SK, Iberri Jaime AJ, Zambrano Lara M, Jiménez Bobadilla B. Lower gastrointestinal bleeding secondary to appendiceal mucinous neoplasm: a report of two cases and a review of the literature. Cureus. (2024) 16(1):e52908. doi: 10.7759/cureus.52908

PubMed Abstract | Crossref Full Text | Google Scholar

6. Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. (1993) 36(4):323–9. doi: 10.1007/bf02053933

PubMed Abstract | Crossref Full Text | Google Scholar

7. Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, et al. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br J Surg. (2014) 101(13):1758–65. doi: 10.1002/bjs.9674

PubMed Abstract | Crossref Full Text | Google Scholar

8. Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. (2019) 3(2):195–202. doi: 10.1002/bjs5.97

PubMed Abstract | Crossref Full Text | Google Scholar

9. Nizam W, Fackche N, Pessoa B, Kubi B, Cloyd JM, Grotz T, et al. Prognostic significance of preoperative tumor markers in pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasm: a study from the US HIPEC collaborative. J Gastrointest Surg. (2022) 26(2):414–24. doi: 10.1007/s11605-021-05075-1

PubMed Abstract | Crossref Full Text | Google Scholar

10. Ghelardi F, Raimondi A, Morano F, Randon G, Pannone A, Guaglio M, et al. Mytomicin-C, metronomic capecitabine, and bevacizumab in patients with unresectable or relapsed pseudomyxoma peritonei of appendiceal origin. Clin Colorectal Cancer. (2023) 22(4):450–456.e1. doi: 10.1016/j.clcc.2023.08.005

PubMed Abstract | Crossref Full Text | Google Scholar

11. Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the national cancer data base. Cancer. (2016) 122(2):213–21. doi: 10.1002/cncr.29744

PubMed Abstract | Crossref Full Text | Google Scholar

12. Shimoyama S, Kuramoto S, Kawahara M, Yamasaki K, Endo H, Murakami T, et al. A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis. J Gastroenterol Hepatol. (2001) 16(7):825–9. doi: 10.1046/j.1440-1746.2001.02401.x

PubMed Abstract | Crossref Full Text | Google Scholar

13. Rickes S, Malfertheiner P. Splenic metastases in pseudomyxoma peritonei. Med Klin (Munich). (2004) 99(12):749–50. doi: 10.1007/s00063-004-1111-9

PubMed Abstract | Crossref Full Text | Google Scholar